105 related articles for article (PubMed ID: 15030538)
1. A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults.
Baldwin JR; Fleishaker JC; Azie NE; Carel BJ
Cephalalgia; 2004 Apr; 24(4):288-92. PubMed ID: 15030538
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers.
Fleishaker JC; Sisson TA; Carel BJ; Azie NE
Clin Pharmacol Ther; 2000 May; 67(5):498-503. PubMed ID: 10824628
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of sumatriptan nasal spray in adolescents.
Christensen ML; Mottern RK; Jabbour JT; Fuseau E
J Clin Pharmacol; 2003 Jul; 43(7):721-6. PubMed ID: 12856385
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of rizatriptan in healthy elderly subjects.
Musson DG; Birk KL; Panebianco DL; Gagliano KD; Rogers JD; Goldberg MR
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):447-52. PubMed ID: 11680669
[TBL] [Abstract][Full Text] [Related]
5. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
[TBL] [Abstract][Full Text] [Related]
6. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.
Diener HC
Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of oral almotriptan in healthy male volunteers.
McEwen J; Salva M; Jansat JM; Cabarrocas X
Biopharm Drug Dispos; 2004 Oct; 25(7):303-11. PubMed ID: 15386481
[TBL] [Abstract][Full Text] [Related]
8. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
Peck RW; Seaber EJ; Dixon RM; Layton GR; Weatherley BC; Jackson SH; Rolan PE; Posner J
Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
[TBL] [Abstract][Full Text] [Related]
9. Oral almotriptan: practical uses in the acute treatment of migraine.
Dowson AJ
Expert Rev Neurother; 2004 May; 4(3):339-48. PubMed ID: 15853532
[TBL] [Abstract][Full Text] [Related]
10. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of sumatriptan nasal spray in children.
Christensen ML; Mottern RK; Jabbour JT; Fuseau E
J Clin Pharmacol; 2004 Apr; 44(4):359-67. PubMed ID: 15051742
[TBL] [Abstract][Full Text] [Related]
12. [Almotriptan in the treatment of migraine attacks in clinical practice: results of the TEA 2000 observational study].
Pascual J; Láinez JM; Leira R; Titus F; Mateos V; Galván J;
Neurologia; 2003; 18(1):7-17. PubMed ID: 12590376
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
Diamond ML; Cady RK; Mao L; Biondi DM; Finlayson G; Greenberg SJ; Wright P
Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular effect of almotriptan in treated hypertensive patients.
Fleishaker JC; McEnroe JD; Azie NE; Francom SF; Carel BJ
Clin Pharmacol Ther; 2002 Mar; 71(3):169-75. PubMed ID: 11907491
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of frovatriptan in adolescent migraineurs.
Elkind AH; Wade A; Ishkanian G
J Clin Pharmacol; 2004 Oct; 44(10):1158-65. PubMed ID: 15342617
[TBL] [Abstract][Full Text] [Related]
16. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers.
Fleishaker JC; Sisson TA; Carel BJ; Azie NE
Cephalalgia; 2001 Feb; 21(1):61-5. PubMed ID: 11298665
[TBL] [Abstract][Full Text] [Related]
17. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine.
Allais G; Acuto G; Cabarrocas X; Esbri R; Benedetto C; Bussone G
Neurol Sci; 2006 May; 27 Suppl 2():S193-7. PubMed ID: 16688629
[TBL] [Abstract][Full Text] [Related]
19. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine.
McEnroe JD; Fleishaker JC
Clin Pharmacokinet; 2005; 44(3):237-46. PubMed ID: 15762767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
